Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.65 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.52 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.52 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.50 |
| ▸ | F11 | P03951 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31422913 | 0.88 | DAO (0.63) | DAOGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL9249785 | 0.88 | DAO (0.63) | DAOGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1367967 | 0.86 | DAO (0.65) | DAOGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1369702 | 0.85 | DAO (0.59) | DAOGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL10330650 | 0.83 | DAO (0.56) | DAOGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1369396 | 0.81 | CA2 (0.47) | DAOPDGFRBFLT3 | |
| SCHEMBL1369068 | 0.81 | DAO (0.54) | DAOGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6161066 | 0.79 | ALOX15 (0.69) | DAOALOX15GAA | |
| SCHEMBL16767847 | 0.79 | DAO (1.00) | DAOGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1368520 | 0.78 | PADI4 (0.58) | DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275650-A1 | 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-11-05 | — | — | US | claimed |
| WO-2006132947-A2 | 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-12-14 | — | — | WO | claimed |
| US-8067461-B2 | 3-acyl coumarins, thiochromones and quinolones and therapeutic uses thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090275650-A1 | 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2006132947-A2 | 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275650-A1 | 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof | NQO2, NQO1, HCCS | DAO 3402/4885GRIN2D 4606/4885GRIN3B 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.